CARsgen Therapeutics Holdings Limited (Stock Code: 2171), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the first ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Choose from Myeloma Treatment stock illustrations from iStock. Find high-quality royalty-free vector images that you won't find anywhere else. Video Back Videos home Signature collection ... Photos ...

The company's flagship products include OPDIVO, a PD-1 inhibitor used in cancer treatment ... a GPRC5D targeting cell therapy for multiple myeloma. Early trial results have shown high response ...

With the exception of "Editorial use only" photos (which can only be used in editorial projects and can't be modified), the possibilities are limitless. Learn more about royalty-free images or view ...

Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what ...

Also Read: FDA Approves Johnson & Johnson’s Treatment As First Monotherapy ... once again headlined by the very strong multiple myeloma franchise, delivered yet again amid high expectations.

Additionally, stockholders approved an amendment to effectuate a reverse stock ... treatment consisting of Xpovio, Pomalyst, and dexamethasone in patients with previously treated multiple myeloma.

We’ll have to do some demand forecasting for various centres and keep stock accordingly.” AIIMS, Delhi developing low cost adaptive cellular therapy for treatment of multiple myeloma ...

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Na ...